Psychometric Validation of the Growth Hormone Deficiency-Child Impact Measure (GHD-CIM)

Overview

Journal Pharmacoecon Open

Date 2021 Jan 12

PMID 33433896

Citations 6

Authors

Meryl Brod

Michael Hojby Rasmussen

Knud Vad

Suzanne Alolga

Donald M Bushnell

Jacques Bedoin

Aristides Maniatis

Affiliations

Soon will be listed here.

Abstract

Objective: The aim of this study was to perform psychometric testing of the Growth Hormone Deficiency-Child Impact Measure (GHD-CIM): a patient-reported outcome (PRO) for children with GHD aged 9 to < 13 years and an observer-reported outcome (ObsRO) for parents/guardians of children who are unable to answer for themselves.

Methods: A non-interventional, multicenter, clinic-based study was conducted in 30 private-practice and large institutional sites in the US and the UK. Psychometric analyses were conducted following an a priori validation statistical analysis plan.

Results: A preliminary examination of the data determined a PRO version for children aged 9 to < 13 years was not psychometrically sound and therefore the decision was made to have only an ObsRO measure of the GHD-CIM, which would be suitable for children aged 4 to < 13 years. The GHD-CIM ObsRO validity analyses included 98 parents/guardians. Factor analyses identified three domains: Physical Functioning (PHYS), Social Well-Being (SWB), and Emotional Well-Being (EWB). Internal consistency reliability was acceptable for all domains and for the overall score (Cronbach's alpha > 0.70), as was test-retest reliability for the SWB, EWB and overall (above 0.70). At least one convergent validity hypotheses for each domain and overall was proven (r > 0.40). Known-groups validity hypotheses for the EWB and SWB domains were significant (p < 0.05). Associated effect sizes ranged from - 0.40 to - 0.58, indicating that the GHD-CIM is sensitive to change. Anchor-based patient and clinician ratings of severity of disease suggest a preliminary minimally important difference of 5 points for the overall score, and 5 for PHYS, 7 for EWB, and 5 for SWB.

Conclusions: The GHD-CIM ObsRO was found to be a reliable and valid measure to assess disease-specific functioning, which will provide a more complete patient-centric picture to the growth hormone therapy experience in children.

Trial Registration: ClinicalTrials.gov NCT02580032, first posted 20 October 2015.

Citing Articles

Once-Weekly Somapacitan as an Alternative Management of Growth Hormone Deficiency in Prepubertal Children: A Systematic Review and Meta-Analysis of Randomized Controlled Trial.

Tsurayya G, Nazhifah C, Pirwanja M, Zulfa P, Tatroman M, Fakri F Children (Basel). 2024; 11(2).

PMID: 38397339 PMC: 10887308. DOI: 10.3390/children11020227.

Weekly Somapacitan in GH Deficiency: 4-Year Efficacy, Safety, and Treatment/Disease Burden Results From REAL 3.

Savendahl L, Battelino T, Rasmussen M, Brod M, Rohrich S, Saenger P J Clin Endocrinol Metab. 2023; 108(10):2569-2578.

PMID: 36995872 PMC: 10505532. DOI: 10.1210/clinem/dgad183.

Long-acting growth hormone in 2022.

Steiner M, Frank J, Saenger P Pediatr Investig. 2023; 7(1):36-42.

PMID: 36967745 PMC: 10030690. DOI: 10.1002/ped4.12358.

Psychometric Validation of the Growth Hormone Deficiency-Child Treatment Burden Measure (GHD-CTB) and the Growth Hormone Deficiency-Parent Treatment Burden Measure (GHD-PTB).

Brod M, Rasmussen M, Alolga S, Beck J, Bushnell D, Lee K Pharmacoecon Open. 2022; 7(1):121-138.

PMID: 36255609 PMC: 9929004. DOI: 10.1007/s41669-022-00373-z.

Weekly Somapacitan is Effective and Well Tolerated in Children With GH Deficiency: The Randomized Phase 3 REAL4 Trial.

Miller B, Blair J, Rasmussen M, Maniatis A, Kildemoes R, Mori J J Clin Endocrinol Metab. 2022; 107(12):3378-3388.

PMID: 36062966 PMC: 9693810. DOI: 10.1210/clinem/dgac513.

References

Lindsay R, Feldkamp M, Harris D, Robertson J, Rallison M . Utah Growth Study: growth standards and the prevalence of growth hormone deficiency. J Pediatr. 1994; 125(1):29-35. DOI: 10.1016/s0022-3476(94)70117-2. View

Thomas M, Massa G, Craen M, de Zegher F, Bourguignon J, Heinrichs C . Prevalence and demographic features of childhood growth hormone deficiency in Belgium during the period 1986-2001. Eur J Endocrinol. 2004; 151(1):67-72. DOI: 10.1530/eje.0.1510067. View

Whiteside S . Adapting the Sheehan disability scale to assess child and parent impairment related to childhood anxiety disorders. J Clin Child Adolesc Psychol. 2010; 38(5):721-30. DOI: 10.1080/15374410903103551. View

Wyrwich K, Nienaber N, Tierney W, Wolinsky F . Linking clinical relevance and statistical significance in evaluating intra-individual changes in health-related quality of life. Med Care. 1999; 37(5):469-78. DOI: 10.1097/00005650-199905000-00006. View

Souza F, Collett-Solberg P . Adverse effects of growth hormone replacement therapy in children. Arq Bras Endocrinol Metabol. 2012; 55(8):559-65. DOI: 10.1590/s0004-27302011000800009. View

Bullinger M, Quitmann J, Power M, Herdman M, Mimoun E, DeBusk K . Assessing the quality of life of health-referred children and adolescents with short stature: development and psychometric testing of the QoLISSY instrument. Health Qual Life Outcomes. 2013; 11:76. PMC: 3666886. DOI: 10.1186/1477-7525-11-76. View

Guyatt G, Osoba D, Wu A, Wyrwich K, Norman G . Methods to explain the clinical significance of health status measures. Mayo Clin Proc. 2002; 77(4):371-83. DOI: 10.4065/77.4.371. View

. Guidelines for good pharmacoepidemiology practices (GPP). Pharmacoepidemiol Drug Saf. 2007; 17(2):200-8. DOI: 10.1002/pds.1471. View

Bullinger M, Schmidt S, Petersen C . Assessing quality of life of children with chronic health conditions and disabilities: a European approach. Int J Rehabil Res. 2002; 25(3):197-206. DOI: 10.1097/00004356-200209000-00005. View

10.

Grimberg A, DiVall S, Polychronakos C, Allen D, Cohen L, Quintos J . Guidelines for Growth Hormone and Insulin-Like Growth Factor-I Treatment in Children and Adolescents: Growth Hormone Deficiency, Idiopathic Short Stature, and Primary Insulin-Like Growth Factor-I Deficiency. Horm Res Paediatr. 2016; 86(6):361-397. DOI: 10.1159/000452150. View

11.

Vimpani G, Vimpani A, Lidgard G, Cameron E, Farquhar J . Prevalence of severe growth hormone deficiency. Br Med J. 1977; 2(6084):427-30. PMC: 1631237. DOI: 10.1136/bmj.2.6084.427. View

12.

. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013; 310(20):2191-4. DOI: 10.1001/jama.2013.281053. View

13.

PRADER A, Largo R, Molinari L, Issler C . Physical growth of Swiss children from birth to 20 years of age. First Zurich longitudinal study of growth and development. Helv Paediatr Acta Suppl. 1989; 52:1-125. View

14.

. Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance. Health Qual Life Outcomes. 2006; 4:79. PMC: 1629006. DOI: 10.1186/1477-7525-4-79. View

15.

Snoek F, Mollema E, Heine R, Bouter L, VAN DER Ploeg H . Development and validation of the diabetes fear of injecting and self-testing questionnaire (D-FISQ): first findings. Diabet Med. 1997; 14(10):871-6. DOI: 10.1002/(SICI)1096-9136(199710)14:10<871::AID-DIA457>3.0.CO;2-Y. View

16.

Brod M, Alolga S, Beck J, Wilkinson L, Hojbjerre L, Rasmussen M . Understanding burden of illness for child growth hormone deficiency. Qual Life Res. 2017; 26(7):1673-1686. PMC: 5486907. DOI: 10.1007/s11136-017-1529-1. View

17.

Matza L, Patrick D, Riley A, Alexander J, Rajmil L, Pleil A . Pediatric patient-reported outcome instruments for research to support medical product labeling: report of the ISPOR PRO good research practices for the assessment of children and adolescents task force. Value Health. 2013; 16(4):461-79. DOI: 10.1016/j.jval.2013.04.004. View